Evaluating left atrial size changes after cardioversion in patients with persistent atrial fibrillation
Association of Left Atrial Volume Changes After Cardioversion and Recurrence of Atrial Fibrillation After Radiofrequency Ablation in Patients With Persistent Atrial Fibrillation
This study is testing if changes in the size of the left atrium after treatment for atrial fibrillation can help predict how likely it is for the condition to come back in patients who have had a procedure to fix it.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The Second Affiliated Hospital of Chongqing Medical University Academic / other |
| Locations | 1 site (Chongqing, Chongqing Municipality) |
| Trial ID | NCT06523738 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the relationship between changes in left atrial size following electrical or pharmacological cardioversion and the recurrence of atrial fibrillation (AF) after radiofrequency ablation in patients with persistent AF. Participants will undergo echocardiograms before and 3-6 months after cardioversion to measure left atrial diameter. The hypothesis is that greater reductions in left atrial size will correlate with lower rates of AF recurrence post-ablation. The study focuses on understanding how structural remodeling of the left atrium can impact long-term outcomes for AF patients.
Who should consider this trial
Good fit: Ideal candidates are patients diagnosed with persistent atrial fibrillation who have undergone successful cardioversion and have specific left atrial dimensions.
Not a fit: Patients who have previously undergone radiofrequency ablation or cardiac surgical procedures may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help identify patients at lower risk of AF recurrence after treatment, leading to more personalized and effective management strategies.
How similar studies have performed: While the relationship between left atrial size and AF recurrence has been explored, this specific approach focusing on persistent AF and cardioversion outcomes is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with estabolished diagnosis of Persistent Atrial Fibrillation during past 6 mnths. 2. LAD brfore entering the two cohorts is more than 40mm, and less than 50mm. 3. Pharmacological or electrical cardioversion has be performed successfully. 4. At least two echocardiograms were performed before and 3-6 months after cardioversion., and confirm the status of LAD (Reversal, unchange, enlargment). 5. Patients have given informed consent. Exclusion Criteria: 1. Prior radiofrequency ablation treatment for atrial fibrillation 2. Prior cardiac surgical procedures 3. Individuals with cognitive impairments who are unable to give informed consent
Where this trial is running
Chongqing, Chongqing Municipality
- The Second Affiliated Hospital of Chongqing Medical University — Chongqing, Chongqing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Yuehui Yin, MD
- Email: yinyh@hospital.cqmu.edu.cn; yinyh63@163.com
- Phone: +8613508335502
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.